Physician profile
Ronald L Meisel
NPI 1851338156
$2,418.88
in general payments reported to CMS, 2019-2025
14 companies · $541 in 2025
The $541 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $257 · 2020: $127 · 2022: $434 · 2023: $251 · 2024: $809 · 2025: $541.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,601.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,601.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $676.64 | 2019-2025 | Bone Anchors With Arthroscopic Delivery System, Healicoil, Firstpass |
| Depuy Synthes Sales INC. | $313.51 | 2019-2025 | Tfn-Advance, Na |
| Heron Therapeutics, INC. | $282.42 | 2022-2025 | Zynrelef |
| Stryker Corporation | $279.89 | 2019-2024 | Mako |
| Pinnacle, INC | $186.22 | 2024 | |
| Davol INC. | $126.63 | 2024 | |
| Acera Surgical, INC. | $110.44 | 2025 | Restrata Wound Matrix |
| Vertex Pharmaceuticals Incorporated | $91.23 | 2025 | |
| Polynovo North America LLC | $87.84 | 2024 | Novosorb Btm |
| Orthofix Medical, INC. | $87.40 | 2023 | Physio-Stim |
| Si-Bone, INC. | $82.25 | 2025 | |
| Kerecis Limited | $59.46 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Medical Device Business Services, INC. | $17.81 | 2024 | Velys |
| Organogenesis INC. | $17.14 | 2025 | Puraply Wound Matrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Meisel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.